Print

Active Biotech AB Interim report January - September 2012

2012-11-09

·Laquinimod- Teva to initiate a new Phase III study in the US at year-end
- milestone payment of USD 5 M received following a submitted application for regulatory approval in Europe
-Crohn's Phase II data presented at the UEGW conference

·TASQ - biomarker data presented at the ESMO conference
- Ipsen to initiate two new clinical Phase II studies: maintenance therapy for prostate cancer and a study of other types of cancer

·ANYARA - Phase III study results to be presented Q1 2013

·57-57 - clinical trial of systemic sclerosis/scleroderma is in progress

·ISI - project proceeding as planned

·Net sales: SEK 136.4 M (231.3)

·Operating loss: SEK 168.7 M (loss 6.2)

·Loss after tax: SEK 175.1 M (loss: 1.3)

·Loss per share for the period: SEK 2.54 (loss: 0.02)


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech AB Interim report January - September 2012



Back